Evaluate early-stage assets in pipeline, pharma expert says

01/14/2013 | Forbes

It is important to analyze a pharmaceutical company’s entire pipeline, not just its drugs in late-stage trials, says John LaMattina, a former Pfizer R&D president and senior partner at PureTech Ventures. The information will indicate a company's therapeutic priority areas and strategies. He says some drug companies are very transparent with information about their early-stage assets.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA